Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process. The product aims to address a market of approximately 470,000 cases for knee cartilage repair annually in the U.S., where no off-the-shelf treatment is available. Regentis views the European launch as a critical milestone before pursuing U.S. regulatory approval.
The surgeon training program reflects Regentis's commitment to ensuring that clinicians are proficient in the GelrinC procedure, which is designed as a single-step implant. The company expects that the Centers of Excellence will play a vital role in building confidence among surgeons and supporting widespread adoption. The training at Humanitas Research Hospital will serve as a model for future sessions across Europe.
Regentis Biomaterials is a regenerative medicine company focused on developing tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged tissue including cartilage and bone. For more information, visit the company’s newsroom at https://ibn.fm/RGNT.
This announcement underscores the company's progress in bringing GelrinC to market, potentially offering a new treatment option for patients with knee cartilage lesions. The training initiative is a concrete step toward making the technology available to surgeons and patients in Europe.
